Melanoxetin: A Hydroxylated Flavonoid Attenuates Oxidative Stress and Modulates Insulin Resistance and Glycation Pathways in an Animal Model of Type 2 Diabetes Mellitus

Journal Article · Fri Feb 09 00:00:00 EST 2024 · Pharmaceutics

DOI:https://doi.org/10.3390/pharmaceutics16020261· OSTI ID:2294143

Rocha, Sónia ; Amaro, Andreia ; Ferreira-Junior, Marcos D. ; Proença, Carina; Silva, Artur M. S. ; Costa, Vera M. ; Oliveira, Sara ; Fonseca, Diogo A. ; Silva, Sónia ; Corvo, Maria Luísa ; Freitas, Marisa ; Matafome, Paulo ; Fernandes, Eduarda

Type 2 diabetes mellitus (DM) continues to escalate, necessitating innovative therapeutic approaches that target distinct pathways and address DM complications. Flavonoids have been shown to possess several pharmacological activities that are important for DM. This study aimed to evaluate the in vivo effects of the flavonoid melanoxetin using Goto-Kakizaki rats. Over a period of 14 days, melanoxetin was administered subcutaneously to investigate its antioxidant, anti-inflammatory, and antidiabetic properties. The results show that melanoxetin reduced insulin resistance in adipose tissue by targeting protein tyrosine phosphatase 1B. Additionally, melanoxetin counteracted oxidative stress by reducing nitrotyrosine levels and modulating superoxide dismutase 1 and hemeoxygenase in adipose tissue and decreasing methylglyoxal-derived hydroimidazolone (MG-H1), a key advanced glycation end product (AGE) implicated in DM-related complications. Moreover, the glyoxalase 1 expression decreased in both the liver and the heart, correlating with reduced AGE levels, particularly MG-H1 in the heart. Melanoxetin also demonstrated anti-inflammatory effects by reducing serum prostaglandin E2 levels, and increasing the antioxidant status of the aorta wall through enhanced acetylcholine-dependent relaxation in the presence of ascorbic acid. These findings provide valuable insights into melanoxetin’s therapeutic potential in targeting multiple pathways involved in type 2 DM, particularly in mitigating oxidative stress and glycation.

• Sponsoring Organization: USDOE Office of Energy Efficiency and Renewable Energy (EERE), Transportation Office. Fuel Cell Technologies Office
• Grant/Contract Number: PD/BD/145169/2019; UI/BD/154406/2023; 2020.07432.BD; 2020.04126.CEECIND/CP1596/CT0006; SFRH/BPD/110001/2015
• OSTI ID: 2294143
• Journal Information: Pharmaceutics, Journal Name: Pharmaceutics Vol. 16 Journal Issue: 2; ISSN 1999-4923
• Publisher: MDPI AG
• Country of Publication: Switzerland
• Language: English